Wu Zhouliang, Wang Donghuai, Zhang Yu, Zhang Zhe, Shen Chong, Xin Zhongcheng, Feng Yuhong, Hu Hailong
Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Transl Androl Urol. 2023 Dec 31;12(12):1834-1844. doi: 10.21037/tau-23-432. Epub 2023 Dec 15.
Bladder cancer (BC) has attracted significant attention on account of its recurrence as well as mortality. Tumor recurrence plays a significant role in cancer patients' individual treatment. Secreted phosphoprotein 1 (SPP1) has been recognized as a potential target for treating BC and served as a useful biomarker for prognosis; it is commonly tested by immunohistochemistry (IHC). However, this conventional method has the disadvantage of being time-consuming and costly. This study aimed to develop a molecular beacon (MB) for the detection of SPP1 messenger RNA (mRNA) for the recurrence prognosis of BC.
An MB was constructed and applied to image SPP1 mRNA level at both molecular and cellular level. The fluorescence spectra were recorded with a fluorescence spectrophotometer. The effect of SPP1 MB toward the cell viability was performed by Cell Counting Kit-8 (CCK-8) assays. The SPP1 mRNA expression level was measured by quantitative real-time polymerase chain reaction (qRT-PCR). Cancer cells and tissues were analyzed with confocal fluorescence imaging. Correlation, sensitivity, and specificity parameters were calculated.
It was demonstrated that both cancer cells and BC tissues expressed high signal which reflected the expression of SPP1. In addition, 42 cases were detected by MB and divided into two groups according to the fluorescence intensity. The results further suggested that highly expressed SPP1 could predict early tumor recurrence in BC.
The SPP1 MB could be applied as an appropriate approach to predict BC recurrence and patients' prognosis.
膀胱癌(BC)因其复发率和死亡率而备受关注。肿瘤复发在癌症患者的个体化治疗中起着重要作用。分泌型磷蛋白1(SPP1)已被认为是治疗BC的潜在靶点,并作为一种有用的预后生物标志物;通常通过免疫组织化学(IHC)进行检测。然而,这种传统方法存在耗时且成本高的缺点。本研究旨在开发一种分子信标(MB),用于检测SPP1信使核糖核酸(mRNA),以预测BC的复发预后。
构建了一种MB,并将其应用于在分子和细胞水平上成像SPP1 mRNA水平。用荧光分光光度计记录荧光光谱。通过细胞计数试剂盒-8(CCK-8)测定法评估SPP1 MB对细胞活力的影响。通过定量实时聚合酶链反应(qRT-PCR)测量SPP1 mRNA表达水平。用共聚焦荧光成像分析癌细胞和组织。计算相关性、敏感性和特异性参数。
结果表明,癌细胞和BC组织均表达高信号,反映了SPP1的表达。此外,用MB检测了42例病例,并根据荧光强度分为两组。结果进一步表明,高表达的SPP1可预测BC的早期肿瘤复发。
SPP1 MB可作为预测BC复发和患者预后的合适方法。